DXR Daxor
Daxor Corp. is a biotechnology company which develops and manufactures BVA-100 blood volume analyzer, an instrument that measures human blood volume. Its IDANT division provides autologous blood storage; and andrology services, such as semen analysis, sperm washing and general lab testing. The company was founded by Joseph Feldschuh in 1970 and is headquartered in New York, NY.
Company profile
Ticker
DXR
Exchange
Website
CEO
Michael R. Feldschuh
Employees
Incorporated
Location
Fiscal year end
Sector
Industry (SIC)
Boston Scientific • Baxter International • Becton, Dickinson And • 3M • Stryker • Teleflex • Resmed • Hill-Rom • Integra Lifesciences • Nuvasive ...
SEC CIK
Corporate docs
IRS number
132682108
DXR stock data
()
News
Stocks That Hit 52-Week Lows On Friday
16 Apr 21
Stocks That Hit 52-Week Lows On Tuesday
13 Apr 21
Highlights From Day 1 Of Benzinga's Biotech Small Cap Conference
25 Mar 21
Ascendiant Capital Assumes Daxor at Buy, Announces Price Target of $21
25 Mar 21
Daxor Biotech Blood Volume Innovation Is Rapidly Improving Patient Outcomes
25 Mar 21
Press releases
DAXOR CORPORATION TO PARTICIPATE IN BENZINGA BIOTECH SMALL CAP CONFERENCE
18 Mar 21
Daxor to Present at the H.C. Wainwright Global Life Sciences Conference
4 Mar 21
Daxor Corporation Announces $0.48 Per Share NAV Increase and Files Annual Report for Fiscal 2020
26 Feb 21
DAXOR CORPORATION RECEIVES ISO 13485 QUALITY MANAGEMENT SYSTEM CERTIFICATION FOR THE BLOOD VOLUME ANALYZER (BVA-100®)
19 Feb 21
DAXOR CORPORATION AWARDED GRANT FROM THE CENTER FOR ADVANCING POINT OF CARE TECHNOLOGIES (CAPCAT) TO DEVELOP A POINT-OF-CARE BLOOD VOLUME ANALYZER
5 Feb 21
Funds
| Series | Ticker | %Monthly Return ? | $Assets | As of | ||
|---|---|---|---|---|---|---|
| None | DXR | 0 | 0 | 0 | 12.92M | Sep 2020 |
Calendar
15 Mar 21
19 Apr 21
31 Dec 21
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 16 Apr 21 | Feldschuh Michael Richard | Common Stock | Buy | Aquire P | No | No | 10.33 | 4,200 | 43.39K | 158,206 |
| 22 Jul 20 | Edward Feuer | DAXOR COMMON STOCK | Sale back to company | Dispose D | No | No | 19.21 | 1,500 | 28.82K | 0 |
| 22 Jul 20 | of Joseph Feldschuh Estate | DAXOR CORPORATION COMMON STOCK | Sale back to company | Dispose D | No | No | 20 | 225,000 | 4.5M | 2,549,455 |
| 29 Jun 20 | Joy S. Goudie | STOCK OPTIONS ( right to buy ) COMMON STOCK | Grant | Aquire A | No | No | 13.06 | 2,000 | 26.12K | 2,000 |
Institutional ownership Q4 2020
Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.
5.2% owned by funds/institutions
13F holders |
Current |
|---|---|
| Total holders | 9 |
| Opened positions | 1 |
| Closed positions | 2 |
| Increased positions | 3 |
| Reduced positions | 3 |
13F shares |
Current |
|---|---|
| Total value | 2.55M |
| Total shares | 204.05K |
| Total puts | 0 |
| Total calls | 0 |
| Total put/call ratio | – |
Largest owners |
Shares | Value |
|---|---|---|
| Sabby Management | 128.4K | $1.61M |
| Vanguard | 47.33K | $592K |
| Renaissance Technologies | 25.52K | $319K |
| UBS UBS Group AG - Registered Shares | 1.31K | $16K |
| Tower Research Capital | 982 | $12K |
| WFC Wells Fargo & Co. | 288 | $4K |
| MS Morgan Stanley | 175 | $2K |
| Advisory Services Network | 50 | $1K |
| Proequities | 0 | $0 |
Financial reports
N-CEN
Annual report (registered investment company)
15 Mar 21
N-CSR
Certified annual shareholder report (management investment company)
25 Feb 21
N-CSRS
Certified semi-annual shareholder report (management investment company)
21 Aug 20
N-CEN
Annual report (registered investment company)
13 Mar 20
N-CSR
Certified annual shareholder report (management investment company)
28 Feb 20
N-CSRS
Certified semi-annual shareholder report (management investment company)
27 Aug 19
N-CEN/A
Annual report (registered investment company) (amended)
23 May 19
N-CSR/A
Certified annual shareholder report (management investment company) (amended)
22 May 19
N-CEN
Annual report (registered investment company)
17 Mar 19
N-CSR
Certified annual shareholder report (management investment company)
1 Mar 19
Current reports
8-K
Breakthrough Patent-pending Tracer Developed for Broad Use
15 Mar 21
8-K
Other Events
5 Oct 20
8-K
Daxor Corporation Announces Pricing of $7.0 Million Registered Direct Offering
21 Jul 20
8-K
Daxor Announces Prospective Randomized Control Trial at Duke University Medical Center to Guide Volume Treatment In Heart Failure Patients
16 Jul 20
8-K
Daxor Announces Initiation of First-of-It’s-Kind Multicenter BVA-100® Study in Hospitalized Patients with COVID-19
15 Jul 20
8-K
Daxor Corporation Announces Appointment of Henry D. Cremisi, MD, FACP and Joy Goudie, Esq. to the Company’s Board of Directors
1 Jul 20
8-K
Other Events
6 May 20
8-K
Other Events
23 Apr 20
8-K
Departure of Directors or Certain Officers
28 Sep 18
8-K
Amendments to the Registrant's Code of Ethics, or Waiver of a Provision of the Code of Ethics
15 May 17
Proxies
N-PX
Annual report of proxy voting record
31 Aug 20
DEF 14A
Definitive proxy
4 Jun 20
N-PX
Annual report of proxy voting record
30 Aug 19
DEFR14A
Revised proxy
2 Jun 19
DEF 14A
Definitive proxy
30 May 19
N-PX
Annual report of proxy voting record
10 Jul 18
N-PX/A
Annual report of proxy voting record (amended)
12 Jun 18
DEF 14A
Definitive proxy
22 May 18
DEF 14A
Definitive proxy
13 Nov 17
N-PX
Annual report of proxy voting record
29 Aug 17
Other
EFFECT
Notice of effectiveness
15 Jul 20
CORRESP
Correspondence with SEC
12 Jul 20
EFFECT
Notice of effectiveness
23 May 19
CORRESP
Correspondence with SEC
19 May 19
CORRESP
Correspondence with SEC
16 May 19
CORRESP
Correspondence with SEC
9 May 19
CORRESP
Correspondence with SEC
9 May 19
CORRESP
Correspondence with SEC
2 May 19
CORRESP
Correspondence with SEC
2 Apr 19
EFFECT
Notice of effectiveness
19 Aug 18
Ownership
4
DAXOR / Michael Richard Feldschuh ownership change
16 Apr 21
NPORT-P
None (Sep 2020 report)
21 Oct 20
4
DAXOR / of Joseph Feldschuh Estate ownership change
3 Aug 20
4
DAXOR / Edward Feuer ownership change
3 Aug 20
3
DAXOR / of Joseph Feldschuh Estate ownership change
3 Aug 20
4
DAXOR / JAMES A LOMBARD ownership change
29 Jul 20
4
DAXOR / MARTIN S WOLPOFF ownership change
15 Jul 20
4
DAXOR / Bernhard Saxe ownership change
9 Jul 20
4
DAXOR / Henry D. Cremisi ownership change
9 Jul 20
4
DAXOR / Joy S. Goudie ownership change
9 Jul 20
Patents
APP
Utility
Remote Blood Volume Monitor
23 Sep 20
Systems and methods are disclosed for providing ongoing monitoring and updating of blood volume status, where the system or method can include guidance in the form of recommendations for treatment actions or alerts about altered patient status.
APP
Utility
Flow-through Quantitative Blood Collection Vial
29 Apr 20
A device is presented for storing, transporting, measuring, and collecting blood, having the properties of a precisely determined volume, the ability to be emptied or filled while connected to a continuous source (such as a supply of a drug, or the bloodstream of a patient), and a geometry suitable for the entire device to be placed in the counting chamber of a detector (such as the counting well of a gamma counter).
APP
Utility
Blood Volume Analyzer with Guidance
29 Apr 20
Systems and methods are provided for analyzing blood of a living being, and for presenting guidance for medical treatment.
APP
Utility
Whole Blood Volume Analyzer
29 Apr 20
Systems and methods are provided for measuring blood volume of a living being.